Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence--the Australian experience.
作者信息
Hill S, Henry D, Pekarsky B, Mitchell A
机构信息
Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle, Callaghan, New South Wales, Australia.
出版信息
Br J Clin Pharmacol. 1997 Nov;44(5):421-5. doi: 10.1046/j.1365-2125.1997.t01-1-00597.x.
Abstract
摘要
相似文献
1
Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence--the Australian experience.
Br J Clin Pharmacol. 1997 Nov;44(5):421-5. doi: 10.1046/j.1365-2125.1997.t01-1-00597.x.
2
Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?
J R Soc Med. 2017 Mar;110(3):98-103. doi: 10.1177/0141076817690395. Epub 2017 Jan 24.
3
Clinical trials and health economics--a marriage of convenience or a marriage made in heaven?
J Med Econ. 2008;11(3):541-6. doi: 10.3111/13696990802363015.
4
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Aust Health Rev. 2017 Mar;41(1):1-6. doi: 10.1071/AH15122.
5
[Guidelines for economic evaluation of pharmaceuticals in Korea].
J Prev Med Public Health. 2008 Mar;41(2):80-3. doi: 10.3961/jpmph.2008.41.2.80.
6
Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: A Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States.
Int J Pharm Compd. 2015 Nov-Dec;19(6):514-20.
7
[Real-world studies for answering real-world questions].
Dtsch Med Wochenschr. 2005 Jul 8;130 Suppl 2:S77-81. doi: 10.1055/s-2005-870875.
8
Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis.
N Z Med J. 2013 Jul 12;126(1378):60-73.
9
[Analysis of the economic evaluation of drugs in primary care: concept, methodology and practical applications].
Aten Primaria. 1997 Dec;20(10):563-8.
10
引用本文的文献
1
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.
Global Health. 2005 Oct 6;1:15. doi: 10.1186/1744-8603-1-15.
2
Drug policy down under: Australia's pharmaceutical benefits scheme.
Health Care Financ Rev. 2004 Spring;25(3):55-67.
3
Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
Pharmacoeconomics. 2003;21(1):61-74. doi: 10.2165/00019053-200321010-00005.
4
The need for pharmacoeconomic evaluations in the NHS.
Pharmacoeconomics. 1998 Sep;14(3):241-50. doi: 10.2165/00019053-199814030-00001.
Zotero 插件